185 related articles for article (PubMed ID: 11405345)
1. Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk.
Van den Hout JM; Reuser AJ; de Klerk JB; Arts WF; Smeitink JA; Van der Ploeg AT
J Inherit Metab Dis; 2001 Apr; 24(2):266-74. PubMed ID: 11405345
[TBL] [Abstract][Full Text] [Related]
2. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
Van den Hout JM; Kamphoven JH; Winkel LP; Arts WF; De Klerk JB; Loonen MC; Vulto AG; Cromme-Dijkhuis A; Weisglas-Kuperus N; Hop W; Van Hirtum H; Van Diggelen OP; Boer M; Kroos MA; Van Doorn PA; Van der Voort E; Sibbles B; Van Corven EJ; Brakenhoff JP; Van Hove J; Smeitink JA; de Jong G; Reuser AJ; Van der Ploeg AT
Pediatrics; 2004 May; 113(5):e448-57. PubMed ID: 15121988
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients.
Van den Hout H; Reuser AJ; Vulto AG; Loonen MC; Cromme-Dijkhuis A; Van der Ploeg AT
Lancet; 2000 Jul; 356(9227):397-8. PubMed ID: 10972374
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.
Klinge L; Straub V; Neudorf U; Schaper J; Bosbach T; Görlinger K; Wallot M; Richards S; Voit T
Neuromuscul Disord; 2005 Jan; 15(1):24-31. PubMed ID: 15639117
[TBL] [Abstract][Full Text] [Related]
5. Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.
Winkel LP; Kamphoven JH; van den Hout HJ; Severijnen LA; van Doorn PA; Reuser AJ; van der Ploeg AT
Muscle Nerve; 2003 Jun; 27(6):743-51. PubMed ID: 12766987
[TBL] [Abstract][Full Text] [Related]
6. Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II.
Bijvoet AG; Van Hirtum H; Kroos MA; Van de Kamp EH; Schoneveld O; Visser P; Brakenhoff JP; Weggeman M; van Corven EJ; Van der Ploeg AT; Reuser AJ
Hum Mol Genet; 1999 Nov; 8(12):2145-53. PubMed ID: 10545593
[TBL] [Abstract][Full Text] [Related]
7. Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from chinese hamster ovary cells.
Rossi M; Parenti G; Della Casa R; Romano A; Mansi G; Agovino T; Rosapepe F; Vosa C; Del Giudice E; Andria G
J Child Neurol; 2007 May; 22(5):565-73. PubMed ID: 17690063
[TBL] [Abstract][Full Text] [Related]
8. Enzyme therapy for Pompe disease: from science to industrial enterprise.
Reuser AJ; Van Den Hout H; Bijvoet AG; Kroos MA; Verbeet MP; Van Der Ploeg AT
Eur J Pediatr; 2002 Oct; 161 Suppl 1():S106-11. PubMed ID: 12373583
[TBL] [Abstract][Full Text] [Related]
9. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
[TBL] [Abstract][Full Text] [Related]
10. Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease.
Cook AL; Kishnani PS; Carboni MP; Kanter RJ; Chen YT; Ansong AK; Kravitz RM; Rice H; Li JS
Genet Med; 2006 May; 8(5):313-7. PubMed ID: 16702882
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study.
Klinge L; Straub V; Neudorf U; Voit T
Neuropediatrics; 2005 Feb; 36(1):6-11. PubMed ID: 15776317
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study.
Hahn SH; Kronn D; Leslie ND; Pena LDM; Tanpaiboon P; Gambello MJ; Gibson JB; Hillman R; Stockton DW; Day JW; Wang RY; An Haack K; Shafi R; Sparks S; Zhao Y; Wilson C; Kishnani PS;
Genet Med; 2018 Oct; 20(10):1284-1294. PubMed ID: 29565424
[TBL] [Abstract][Full Text] [Related]
13. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up.
Winkel LP; Van den Hout JM; Kamphoven JH; Disseldorp JA; Remmerswaal M; Arts WF; Loonen MC; Vulto AG; Van Doorn PA; De Jong G; Hop W; Smit GP; Shapira SK; Boer MA; van Diggelen OP; Reuser AJ; Van der Ploeg AT
Ann Neurol; 2004 Apr; 55(4):495-502. PubMed ID: 15048888
[TBL] [Abstract][Full Text] [Related]
14. Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease.
Levine JC; Kishnani PS; Chen YT; Herlong JR; Li JS
Pediatr Cardiol; 2008 Nov; 29(6):1033-42. PubMed ID: 18661169
[TBL] [Abstract][Full Text] [Related]
15. Use of cardiac magnetic resonance imaging to evaluate cardiac structure, function and fibrosis in children with infantile Pompe disease on enzyme replacement therapy.
Barker PC; Pasquali SK; Darty S; Ing RJ; Li JS; Kim RJ; DeArmey S; Kishnani PS; Campbell MJ
Mol Genet Metab; 2010 Dec; 101(4):332-7. PubMed ID: 20875764
[TBL] [Abstract][Full Text] [Related]
16. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease.
Kishnani PS; Nicolino M; Voit T; Rogers RC; Tsai AC; Waterson J; Herman GE; Amalfitano A; Thurberg BL; Richards S; Davison M; Corzo D; Chen YT
J Pediatr; 2006 Jul; 149(1):89-97. PubMed ID: 16860134
[TBL] [Abstract][Full Text] [Related]
17. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease.
Peng J; Dalton J; Butt M; Tracy K; Kennedy D; Haroldsen P; Cahayag R; Zoog S; O'Neill CA; Tsuruda LS
J Pharmacol Exp Ther; 2017 Feb; 360(2):313-323. PubMed ID: 27856936
[TBL] [Abstract][Full Text] [Related]
18. Cardiac outcome in classic infantile Pompe disease after 13 years of treatment with recombinant human acid alpha-glucosidase.
van Capelle CI; Poelman E; Frohn-Mulder IM; Koopman LP; van den Hout JMP; Régal L; Cools B; Helbing WA; van der Ploeg AT
Int J Cardiol; 2018 Oct; 269():104-110. PubMed ID: 30049495
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human acid alpha-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice.
Bijvoet AG; Kroos MA; Pieper FR; Van der Vliet M; De Boer HA; Van der Ploeg AT; Verbeet MP; Reuser AJ
Hum Mol Genet; 1998 Oct; 7(11):1815-24. PubMed ID: 9736785
[TBL] [Abstract][Full Text] [Related]
20. A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.
Byrne BJ; Geberhiwot T; Barshop BA; Barohn R; Hughes D; Bratkovic D; Desnuelle C; Laforet P; Mengel E; Roberts M; Haroldsen P; Reilley K; Jayaram K; Yang K; Walsh L;
Orphanet J Rare Dis; 2017 Aug; 12(1):144. PubMed ID: 28838325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
